EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer

Mitchell S von Itzstein, Sawsan Rashdan, Suzanne E Dahlberg, David E Gerber iD, Alan B Sandler, Joan H Schiller, David H Johnson, Yating Wang, Zhuoxin Sun, Suresh S Ramalingam

The Oncologist · 10.03.2025 · 30 (3)

DOI: 10.1093/oncolo/oyaf036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 27.03.2025. Verfasst von Mitchell S von Itzstein und 9 weiteren Autor:innen. Beteiligte Einrichtung: Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, United States. Hauptthemen laut MEDLINE: Peripheral Nervous System Diseases, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute of the National Institutes of Health, ECOG-ACRIN Cancer Research Group.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High-grade chemotherapy-induced peripheral neuropathy (CIPN) represents a dreaded toxicity of cancer treatments. In some cases, it may limit activities of daily living and become permanent. Because many prior studies of CIPN were conducted in breast cancer populations, less is known about CIPN in men. We therefore determined the incidence and correlates of high-grade CIPN in a large cohort of patients with lung cancer.

Methods

We collected data from the ECOG-ACRIN E1594 (comparison of 4 chemotherapy regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, carboplatin-paclitaxel) and E4599 (carboplatin-paclitaxel ± concurrent and maintenance bevacizumab) clinical trials. We identified cases with grade ≥3 CIPN. Multivariable logistic regression modeling was performed to estimate adjusted odds ratios according to patient characteristics.

Results

Among 1,998 patients included in the study, 167 (8%) developed grade ≥3 CIPN. Grade ≥3 CIPN was associated with higher body mass index (BMI) (P = .01), sex (7% for men vs 10% for women; P = .005), age (11% for ≥65 years vs 7% for <65 years; P < .001), chemotherapy regimen (P = .01), and greater number treatment cycles (P < .001). In a multivariate model, regimens featuring higher doses of paclitaxel or cisplatin, greater number of chemotherapy cycles, female sex, greater age, and higher BMI remained independently associated with grade ≥3 CIPN.

Conclusions

High-grade CIPN is associated with chemotherapy type and exposure, female sex, greater age, and elevated BMI. Given the ongoing use of cytotoxic agents in established and new (eg, antibody-drug conjugates) treatment regimens, these findings have implications for patient monitoring and treatment selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripheral Nervous System DiseasesLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedMiddle AgedCisplatinPaclitaxelCarboplatinDocetaxelIncidenceDeoxycytidineGemcitabineTaxoidsAdult

Stichwörter der Autor:innen

CIPNchemotherapyneuropathynonsmall cell lung cancertoxicity

Substanzen

CisplatinPaclitaxelCarboplatinDocetaxelDeoxycytidineGemcitabineTaxoids

Autor:innen und Institutionen

  • Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, United States.
  • Dana Farber Cancer Institute, Boston, MA, United States.
  • Oregon Health Sciences University, Portland, OR, United States.
  • Vanderbilt University, Nashville, TN, United States.
  • Winship Cancer Center, Emory University, Atlanta, GA, United States.

ORCID-Profile: David E Gerber

Förderung

  • NCI NIH HHS
  • National Cancer Institute of the National Institutes of Health
  • ECOG-ACRIN Cancer Research Group

Zitieren

APA

von Itzstein, M. S., Rashdan, S., Dahlberg, S. E., Gerber, D. E., Sandler, A. B., Schiller, J. H., Johnson, D. H., Wang, Y., Sun, Z., & Ramalingam, S. S. (2025). Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer. The Oncologist, 30(3). https://doi.org/10.1093/oncolo/oyaf036

Vancouver

von Itzstein MS, Rashdan S, Dahlberg SE, Gerber DE, Sandler AB, Schiller JH, et al. Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer. The Oncologist. 2025;30(3). doi:10.1093/oncolo/oyaf036

BibTeX
@article{vonItzstein2025,
  author = {von Itzstein, Mitchell S and Rashdan, Sawsan and Dahlberg, Suzanne E and Gerber, David E and Sandler, Alan B and Schiller, Joan H and Johnson, David H and Wang, Yating and Sun, Zhuoxin and Ramalingam, Suresh S},
  title = {Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {3},
  doi = {10.1093/oncolo/oyaf036}
}
Kostenlos starten →